The Seattle Heart Failure Model: Prediction of survival in heart failure

Circulation

Volumn 113, Issue 11, 2006, Pages 1424-1433

  Levy, Wayne C ^a,l   Mozaffarian, Dariush ^b   Linker, David T ^a   Sutradhar, Santosh C ^c   Anker, Stefan D ^d   Cropp, Anne B ^e   Anand, Inder ^f   Maggioni, Aldo ^g   Burton, Paul ^h   Sullivan, Mark D ^a   Pitt, Bertram ⁱ   Poole Wilson, Philip A ^d   Mann, Douglas L ^j   Packer, Milton ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g Italian Association of Hospital Cardiologists   (Italy)

^h AMGEN INC   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Diuretics; Heart failure; Hemoglobin; Lymphocytes; Prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; CARDIOVASCULAR AGENT; DIURETIC AGENT; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HEART ASSIST DEVICE; HEART FAILURE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL RATE; VALIDATION PROCESS; AREA UNDER THE CURVE; BIOLOGICAL MODEL; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; FEMALE; FORECASTING; HEART LEFT VENTRICLE FUNCTION; HEART PACING; LIFE EXPECTANCY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ROC CURVE; STATISTICS; SURVIVAL; TREATMENT OUTCOME; UTILIZATION REVIEW; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; DIURETICS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HEMOGLOBINS; HUMANS; LIFE EXPECTANCY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; ROC CURVE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645827323     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.584102     Document Type: Article

References (40)

1. Heart disease and stroke statistics: 2004 update. Available at: http://www.americanheart.org. Accessed April 28, 2004.
2. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-2667.
3. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The REMATCH trial: rationale, design, and end points: Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999;67:723-730.
4. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-2587.
5. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
6. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004;116:300-304.
7. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92:1350-1354.
8. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant. 2004;23:1414-1422.
9. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
10. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
11. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
12. Sullivan MD, Levy WC, Crane BA, Russo JE, Spertus JA. Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am J Cardiol. 2004;94:1577-1580.
13. Huehnergarth KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, McDonald GB, Fishbein DP, Levy WC. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol. 2005;95:1492-1495.
14. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
15. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, Cohn J. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;11:91-98.
16. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
17. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113:650-656.
18. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725-730.
19. Lee S, Spencer A. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J Fam Pract. 2001;50:499-504.
20. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
21. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
23. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708.
24. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-1129.
25. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
26. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, Klassen T, Abraham W. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141:381-390.
27. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44:2166-2172.
28. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
29. Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol. 2005;45:1474-1481.
30. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, Jackson PR. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999;82:325-332.
31. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at: http://www.mortality.org. Accessed September 16, 2004.
32. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-1939.
33. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292-299.
34. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933-1940.
35. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987;75:IV-80-IV-92.
36. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
37. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
38. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol. 2005;95:734-741.
39. Zugck C, Kruger C, Kell R, Korber S, Schellberg D, Kubler W, Haass M. Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. Eur J Heart Fail. 2001;3:577-585.
40. Deng MC, De Meester JM, Smits JM, Heinecke J, Scheld HH, for the Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. BMJ. 2000;321:540-545.